fashion -WSS

fashion

author：comprehensive 2025-10-02 18:47:12 - browse：866

Immunofluorescence image shows CD4+ (green) and CD8+ (yellow) T cells in the microenvironment of a head and neck squamous cell carcinoma. — This immunofluorescence image shows T cells (in green and yellow) in the microenvironment of a head and neck squamous cell carcinoma. Allen Lab/NCI/NIH

Merus said Tuesday that the combination of its experimental drug petosemtamab with the checkpoint inhibitor Keytruda shrank tumors in 62% of patients with head and neck cancer, according to an interim analysis of an ongoing mid-stage clinical trial.

The new efficacy results, derived from a larger number of patients, look similar to an initial disclosure made last week that triggered a 36% increase in Merus’ stock price.

But the Dutch drugmaker on Tuesday withheld additional information from the study related to the safety and durability of petosemtamab’s tumor responses, pending presentation at the annual meeting of the American Society of Clinical Oncology on June 3.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Drug for rare kidney disease narrowly misses mark in clinical trial

hotspot

WSS

It's been 20 years since Dolly the sheep. Where's my clone?

Texas board proposes rules on abortion law emergency exemption

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

With Wegovy coverage, Medicare patients may face high costs

Lasker Awards 2023: Winners in biomedical research

Biotech lab space demand falls sharply

knowledge

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Bright Health sells Medicare Advantage business to Molina

What Kate Middleton's cancer revelation might teach the world

Medicare proposal to cover medical devices draws a mixed reaction

FDA panel to weigh approval of NurOwn, controversial ALS drug

United colonoscopy coverage change 'may cost lives,' doctors say

Medical devices makers are asking for forgiveness, not permission

23andMe had bad news about my health. I wish a person had delivered it

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

Activists slam private health insurers over coverage restrictions

Steward Health Care expansion into Malta flopped

focus

Bring on the sabbaticals for nurses

FDA panel to weigh approval of NurOwn, controversial ALS drug

This gene therapy has record $4.25 million price. It's saved children.

Biotech lab space demand falls sharply

Chinese researcher claims birth of first gene

Why are Kaiser Permanente staff considering a strike?

hotspot

knowledge

focus

entertainment